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ABSTRACT 
Background and Purpose: Brain-derived neurotrophic factor (BDNF) levels play an important role in 
neuroplasticity in normal and neurologically compromised individuals. Studies suggest that BDNF levels 
increase in response to physical activity and are also affected by genotype. In individuals with 
Parkinson’s Disease (PD), it is not known if physical activity habits and BDNF genotype modulate this 
neuroprotective response. The purpose of this study was to determine if BDNF genotype interacts with 
lifetime self-reported physical activity levels to affect age of disease onset and severity of PD symptoms, 
specifically gait, balance, and motor dysfunction. 
Methods: Included in this study were 76 individuals with idiopathic PD. DNA collected from buccal cells 
was used to determine BDNF genotype. Self-reported measures included a modified version of the 
Lifetime Physical Activity Questionnaire (LPAQ), the Fear of Falling Avoidance Behavior Questionnaire 
(FFABQ), the Activities-Specific Balance Confidence scale (ABC), and demographic information. Tester-
administered measures included the Mini-Balance Evaluations Test (MiniBESTest) – a gait and balance 
performance battery, and the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale III 
(MDS-UPDRS-III) – an observation assessment of motor function. 
Results: There was no significant interaction between BDNF genotype and self-reported levels of 
physical activity on measures of postural instability. However, participants who, on average, reported 
engaging in more moderate and vigorous activities during their 20s-40s were found to benefit from a 
potential neuroprotective effect of such activity. Higher reported moderate activity during this time 
frame was associated with later disease onset, and a greater number of average hours per week of 
vigorous activity was associated with better gait and balance scores. 
Discussion: Fortunate genetics and a patient reported history of high, habitual physical activity 
throughout the lifespan may be associated with improved function in individuals with PD. Further 
research is needed to confirm this finding as our analyses were underpowered due to small sample size. 
iv 
Still, our findings confirm the importance of living an active lifestyle, particularly, engaging in more 
moderate and vigorous activities during 20s-40s. This information may improve the clinicians’ ability to 
develop individualized treatment plans, can guide individuals at risk for developing PD, and reinforces 
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Epidemiologic research provides evidence that moderate to vigorous aerobic exercise performed 
throughout one’s lifespan decreases the risk of developing PD.1-4 However, the mechanism for this 
protection is not fully understood. One hypothesis is that these effects are mediated in part by increased 
production of brain-derived neurotrophic factor (BDNF).5 BDNF is a neurotrophin, produced in both the 
brain and peripheral tissue, and is critical in neurogenesis and neuroplasticity.6 
 
Increased levels of circulating BDNF promote cell division, regulate neuronal plasticity, and exert a 
protective effect on dopaminergic neurons.7-11 A single bout of high-intensity aerobic exercise increases 
circulating BDNF10 12 13 and is associated with increased motor learning and declarative memory in 
healthy subjects13 and those with PD.12 The brain has been shown to be a source of circulating BDNF at 
rest, and may be a significant contributor to increased plasma BDNF during and following aerobic 
exercise.14 However, an injection of free BDNF into circulation does not result in increased BDNF 
concentration in the brain, due to its inability to cross the blood-brain barrier.15 16 
 
Levels of BDNF production are mediated by a specific gene. A single nucleotide polymorphism (SNP) of 
this gene exists in which the valine at position 66 of the BDNF precursor polypeptide is substituted for 
methionine (known commonly as the Val66Met polymorphism).17 The presence of this substitution 
ultimately decreases the amount of BDNF that is produced.5 In mice, the homozygous Val/Val genotype 
results in the greatest production of BDNF after cerebral ischemic infarct.18 Whereas, at certain stages of 
recovery the homozygous Met/Met genotype results in the lowest average production of BDNF, less 
than half of their Val/Val counterparts.18 A correlation between mice and humans can be made based on 






Initial studies suggest that this genetic polymorphism and aerobic activity levels may interact and 
moderate BDNF production simultaneously. For instance, participants who were post-stroke with a 
Val/Val genotype had a better response to aerobic exercises and activities to promote motor learning 
than participants with either the heterozygous or homozygous Met/Met genotypes.19 While it appears 
unlikely that the Val66Met polymorphism alone affects the age of onset or severity of PD progression,9 it 
is possible that an interaction between BDNF genotype and history of physical activity would. However, 
no studies have yet investigated the effect of and interaction between genotype and exercise on PD 
onset and severity or on physical function in this population. 
 
The primary aim of our study was to determine if BDNF genotype and lifetime physical activity levels 
interacted to influence age of PD diagnosis and current disease severity. We predicted that individuals 
with a homozygous Val66Val genotype and those with higher lifetime physical activity levels would have 
a later disease onset and less severe current PD motor symptoms after controlling for years since onset. 
Another aim was to determine if the BDNF genotype and lifetime physical activity levels were predictive 
of current gait and balance measures while controlling for years since onset. We predicted that 
individuals with a homozygous Val66Val genotype and those with higher lifetime physical activity levels 




The study used a cross-sectional design wherein BDNF genotype and self-reported physical activity 
habits across the lifespan were evaluated for association with year of onset (self-report of age at 




was determined by collecting buccal cells and polymerase chain reaction. This method is preferred as it 
is non-invasive, convenient and relatively inexpensive.  
 
Physical activity levels were determined using a modified version of the Lifetime Physical Activity 
Questionnaire (LPAQ).20 The questionnaire includes questions about time spent sitting, walking, 
performing moderate activity and performing vigorous activity during a total of seven life stages (teens, 
twenties, thirties, forties, fifties, during the five years before diagnosis with PD and during the time since 
diagnosis with PD). Self-reporting of habitual physical activity of various intensities across different 
stages of the lifespan has been shown to have reliability, validity and reproducibility in the LPAQ as well 
as by other developers of similar questionnaires.21 22 Additionally, we tested reliability from a subset of 
participants in this study (n=15, age= 64.3±4.9 years; males= 10, females= 5; Montreal Cognitive 
Assessment (MoCA)=27.2, SD=2.0; years since diagnosis=8.1±5.5) by having participants complete the 
LPAQ twice separated by one week. An Intraclass Correlation Coefficient (ICC(3,1)) showed moderate 
and vigorous physical activity recollection ranged from .77 to .91 at all of the time points between 20-29 
years to 5 years before diagnosis.23 Walking and sitting were more variable for the same time periods 
(ICCs between .29-.82) and were subsequently not used in the analyses. The teen years were also low 
for all activity levels (ICCs<.55) and were, subsequently, not used in the analyses. Likewise, activity levels 
for the time since diagnosis were low (ICCs<.25) except for vigorous activity which was .91. Thus, the 
LPAQ reliability was good for moderate and vigorous physical activity at almost all time points. 
 
PD motor symptoms were measured using the motor subscale (section 3) of the Movement Disorder 
Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)24 and the Hoehn & Yahr Scale.25 The 
Hoehn & Yahr Scale shows stronger reliability and validity in categorizing the progression of PD than the 




used scale for rating the severity of PD and the validity, inter-rater and intra-rater reliability of this 
instrument are well established.27-29 
 
Gait and balance function were quantified using both subject-reported measures, including the Fear of 
Falling Avoidance-Behavior Questionnaire (FFABQ)30 and the Activities-Specific Balance Confidence Scale 
(ABC),31 as well as a clinician-administered measure, the Mini-BESTest,32 all of which have good evidence 
for inter-rater and intra-rater reliability and construct validity in the PD population. 
 
Sample Size Calculation 
Sample size was estimated using the multiple regression module from PASS 16.0 (NCSS, LLC. Kaysville, 
Utah, USA, ncss.com/software/pass) for the two regressions proposed for Aim 1. For the prediction of 
disease onset, 37 participants were needed (α=0.05, 80% power) with one variable (BDNF genotype) 
conservatively estimated to have a low R² of 0.150 entered first and two other variables (average 
moderate 20s to 40s physical activity; average 20s to 40s vigorous physical activity) entered next at low 
to moderate R² of 0.200. For the prediction of current PD motor symptom severity (UPDRS III), 45 
participants were needed (α=0.05, 80% power) with two variables entered first (BDNF genotype, years 
since diagnosis) and conservatively estimated (R² of 0.150) and four other variables (average moderate 
20s to 40s physical activity; average 20s to 40s vigorous physical activity; moderate activity since 
diagnosis; vigorous physical activity since diagnosis) at low to moderate R² of 0.200. 
 
Participants 
Seventy-six individuals with PD participated. To be included, participants had to have idiopathic PD 
diagnosed by a neurologist, based on the Movement Disorder Society (MDS) Clinical Diagnostic 




excellent test-retest reliability with an ICC = 0.97 and good validity for the detection of mild cognitive 
impairment in people with PD. 26 34 Demographic data collected from each participant included gender, 
age, year of diagnosis, fall history, disease stage on the Hoehn and Yahr scale, medications, and time 
since last medication dosage. Recruitment included snowball strategies with participants and recruiting 
visits to PD support groups, community gyms, senior centers, and movement disorder neurologist 
referrals. All participants were consented per the protocol approved by the University of Nevada, Las 
Vegas Institutional Review Board. Because of the design of this study, two different sample sizes were 
used for the analyses. For the primary aim of disease onset, participants diagnosed with early onset PD 
(<50 years at diagnosis) were eliminated from the analysis because their physical activity levels would 
represent averages from 20s to 40s only. This resulted in 60 participants for that analysis (Figure 1). For 
all other analyses, 54 participants were analyzed (Figure 2). Because deep brain stimulation (DBS) would 
be potentially confounding for PD motor symptoms, participants who had had the procedure were 
excluded from those analyses.  
 
Figure 1. Flow diagram for prediction of age at onset subjects. 
 
76 participants diagnosed 
with Parkinson’s disease 
60 participants were 
analyzed for primary aims 
Excluded = 16 
• MoCA<20.5 = 6 
• Age at diagnosis<50 = 10 
15 participants returned 










Data were analyzed using SPSS version 24.0 (SPSS Inc, Chicago, Illinois) at α = 0.05. Hierarchical, multiple 
linear regression analyses were conducted to examine the relationship between predictor variables 
(BDNF genotype and lifetime physical activity levels) on the following dependent variables: disease 
onset (age at diagnosis), PD motor symptoms (MDS-UPDRS III), and measures related to gait and balance 
(MBT, ABC, mFFABQ). For disease onset (year of diagnosis), the following variables were entered into 
the hierarchical model: step 1 (BDNF genotype) and step 2 (average moderate 20s to 40s physical 
activity; average 20s to 40s vigorous physical activity). For PD motor symptoms (MDS-UPDRS III) and gait 
and balance (MBT, ABC, mFFABQ), the following were entered into the model: step 1 (BDNF genotype, 
years since diagnosis) and step 2 (average moderate 20s to 40s physical activity; average 20s to 40s 
vigorous physical activity; moderate activity since diagnosis; vigorous physical activity since diagnosis). 
Dependent variable outliers, defined as those with standardized residual values above 3.3 or below -3.3, 
were screened for removal from the analyses (none identified). Normality, collinearity diagnostics 
(Variance Inflation Factor cutoff of 10), and bivariate correlations were also conducted. There were no 
76 participants diagnosed 
with Parkinson’s disease 
54 participants were 
analyzed for primary aims 
Excluded = 22 (5 had >1 exclusion) 
• MoCA<20.5 = 6 
• Age at diagnosis<50 = 10 
• DBS = 11 
15 participants returned 






major deviations from normality. Due to multicollinearity, the physical activity for the 20s, 30s, and 40s 
was averaged rather than entered into the regression analyses individually. 
 
RESULTS 
Age of PD diagnosis 
The final hierarchical regression model for prediction of age of onset produced an R2 = 0.146 (adjusted 
R2 = 0.099), F(3,58)=3.125, p=.033 (Table 1); however, the only significant variable in the final model was 
the average reported amount of moderate physical activity performed during 20s to 40s (p=.009). 
Neither BDNF genotype (p=.377) or the average amount of vigorous activity during 20s to 40s  (p=.664) 
were statistically significant (Table 2). When the average amount of vigorous activity performed during 
the ages 20s to 40s was removed from the model, the final model R2 was 0.143 (adjusted R2=0.112) and 
was still significant (p=.013). When BDNF genotype was removed from the model, the final R2 decreased 
to 0.115 (adjusted R2=0.100) but was still significant (p=.008). 
Table 1. Model summary for predication of age at PD diagnosis. 
 
Model R R Square Adjusted R Square 
Std. Error of the 
Estimate 
1 .155 .024 .007 7.98 















(Constant) 66.450 3.123  21.277 .000 
BDNF genotype -2.669 2.257 -.155 -1.183 .242 
2 
(Constant) 62.631 3.329  18.813 .000 
BDNF genotype -1.928 2.166 -.112 -.890 .377 
Moderate physical 
activity 20s to 40s .270 .100 .372 2.701 .009 
Vigorous physical 
activity 20s to 40s -.052 .120 -.060 -.437 .664 
 
PD motor symptoms 
The hierarchical regression for UPDRS III was not statistically significant, F(6,52)=.867, p=.526. In the 
final model, none of the variables were statistically significant (ps ≥ .140). 
 
Gait and balance 
The final hierarchical regression for MBT was statistically significant, F(6,52)=2.304, p=.0499. In the final 
model, 23.1% of the variance was explained (R2=.231; adjusted R2=.131) (Table 3). Years since diagnosis 
(p=.014) and average vigorous physical from 20s to 40s (p=.047) were the only two statistically 
significant predictors in the final model (Table 3).  
Table 3. Model summary for predication of MBT score. 
 
Model R R Square Adjusted R Square 
Std. Error of 
the Estimate 
1 .309 .096 .059 5.631 


















(Constant) 23.703 2.586  9.166 .000 
Genotype .836 1.658 .068 .504 .616 
Years since diagnosis -.394 .177 -.300 -2.228 .030 
2 
(Constant) 26.371 2.871  9.186 .000 
BDNF genotype .574 1.686 .047 .340 .735 
Years since diagnosis -.444 .173 -.338 -2.562 .014 
Moderate physical 
activity 20s to 40s -.100 .076 -.190 -1.327 .191 
Vigorous physical 








.062 .165 .063 .373 .711 
 
For the ABC, the final hierarchical model explained 24.7% of the variance, F(6,52)=2.508, p=.035 (Table 
5). In the final model, the only variable that was statistically significant was years since diagnosis 
(p=.002) (Table 6). 
Table 5. Model summary for predication of ABC score. 
 
Model R R Square Adjusted R Square 
Std. Error of 
the Estimate 
1 .410 .168 .135 21.08 















(Constant) 89.203 9.681  9.214 .000 
Genotype .477 6.206 .010 .077 .939 
Years since diagnosis -2.099 .662 -.409 -3.172 .003 
2 
(Constant) 100.01
1 11.090  9.018 .000 
BDNF genotype -1.538 6.512 -.032 -.236 .814 
Years since diagnosis -2.234 .669 -.436 -3.339 .002 
Moderate physical 
activity 20s to 40s -.330 .292 -.160 -1.129 .265 
Vigorous physical 








.445 .637 .116 .698 .489 
 
The final hierarchical model for the prediction of mFFABQ was not statistically significant, F(6,52)=2.052, 
p=.078. The final model explained 21.1% of the variance (R2=.211; adjusted R2=.108) and even though 
years since diagnosis was significant (p=.007), the overall model was not. All of the other variables were 
not statistically significant (ps≥.133). 
 
DISCUSSION 
Our results suggest that self-reported moderate physical activity during the 3rd, 4th, and 5th decades of 
life is associated with age at diagnosis. Specifically, those who reported having spent more time 
participating in moderate physical activity during those three decades were older at diagnosis. This is 
consistent with the notion that exercise may be neuroprotective in PD and is consistent with several 





Our results suggest that every hour increase in weekly moderate physical activity (unstandardized beta = 
.270) was associated with a PD diagnosis a little over a quarter of a year later. While this relationship is 
potentially important from a neuroprotective perspective, it should be noted that moderate physical 
activity only explained 10-14% of the variance of age of onset which suggests that a larger portion of the 
variance remains unexplained by our model; there are clearly other contributors. We had anticipated 
that BDNF might play a role in potentiating the neuroprotection but the low and non-significant 
correlations, though headed in the correct direction (i.e., val/val carriers having an older age at 
diagnosis), suggests that BDNF may only play a minor role. 
 
Other studies have demonstrated similar neuroprotective effects of exercise in PD.1 2 35 38 For example, 
Chen et al reported that men who performed greater baseline physical activity had a decrease risk of 
PD.1 However, contrary to our findings, further analysis by Chen and colleagues revealed that only 
vigorous and not moderate activity was related to the lower risk of PD in their subjects.1 It is important 
to note that their baseline measurements were recorded on subjects ages 30-55, which is an older and 
different lifespan period than our study. Sääksjärvi et al. reported that, compared to those who engaged 
in no heavy leisure-time activity, individuals who performed heavy physical activity were less likely to 
develop PD, relative risk = .27.2 In their study, heavy leisure-time activity was defined as doing greater 
than 3 hours per week of activities such as jogging, skiing, or vigorous gardening.2 A slight protective 
effect of physical activity was also described by Sasco et al, who found that belonging to a varsity team 
in college was associated with a lower nonsignificant risk of PD.35 Moderate physical activity done during 
adulthood was also found to be linked to a reduced risk of PD.35 Yang et al reported an inverse 
association between physical activity and PD as well. However, their team looked at total physical 
activity as compared to the other studies that focused on moderate and vigorous physical activity.4 




studies were large retrospective cohort studies wherein a cohort of healthy individuals were tracked 
over time to see who would eventually develop PD. Thus, they were looking at how physical activity 
influenced the risk of PD. We used a cross-sectional design wherein only individuals already diagnosed 
with PD were included. While each of these studies in isolation is not strong for causal inference of 
neuroprotection in PD, the evidence for causal inference is enhanced by the number of studies 
supporting the construct, the consistency of results across different designs, the strength of 
associations, and the biological plausibility. Taken together, our results suggest a new way of 
investigating the potential protective effect of physical activity in PD.    
 
While moderate lifetime physical activity was predictive of age at diagnosis, vigorous activity was not. 
On the surface, it seems logical that vigorous activity, much like moderate physical activity, would be 
associated with age at diagnosis. However, it is possible that vigorous activity, which is typically close or 
over the anaerobic threshold, would produce more inflammatory signals thereby increasing the 
inflammatory milieu of the individual.39 40 Since inflammation is a known pathophysiologic mechanism 
and a potential disease trigger41 it is possible that engaging in high amounts of vigorous exercise may tip 
the inflammatory balance to a potentially deleterious process. Thus, the issue of exercise/physical 
acitivty dosing warrants additional scientific exploration. 
 
None of the predictor variables in our study were associated with current PD motor symptoms as 
measured by MDS-UPDRS-III score. We had anticipated that greater physical activity and a favorable 
BDNF genotype (i.e., more BDNF produced) would have produced a better neuroprotective 
environment40 42 43 which presumably would have strengthened neural networks associated with motor 
function. This in turn was hypothesized to promote a slower and more protracted decline in motor 




Another noteworthy finding of this study is that two variables predicted gait and balance. First, higher 
balance performance (MBT scores) were achieved by those who engaged in higher amounts of vigorous 
physical activity during their 20s-40s. Evidence suggests that balance responds best to more intense, 
challenge-based training in older adults.44 45 Our study suggests that more vigorous physical activity 
during 20s-40s may also have a carry-over effect on balance later in life. However, further research is 
needed to confirm this proposition. Second, we found that years since diagnosis was negatively 
correlated with balance. Essentially, the longer an individual had been diagnosed with PD the worse 
their gait and balance, represented by a lower MBT score. This is logical and consistent with the 
literature.46 47 
 
Sample recruitment bias is also a major limitation. Most participants were recruited from other research 
studies, most of which investigated the effects of exercise, or were informed of the focus of the study 
prior to participating, leading to possible over reporting of physical activity. In fact, self-reported levels 
of physical activity were remarkably high for the sample tested at all age groups with 78% to 89% of the 
participants reporting having met Centers for Disease Control (CDC) recommendations for physical 
activity48 49 at all stages of their lives. In comparison, only 51% of adults in the United States report 
meeting CDC guidelines for aerobic exercise.50 Additionally, older adults tend to over-estimate the time 
they spend exercising.51 52 A study by Tucker et al found that while 62% of a representative sample of 
Americans self-reported meeting 2008 Physical Activity Guidelines for Americans, only 9.6% of 
participants truly met the guidelines as measured by accelerometer, a pattern that was consistent at all 
age groups (20s, 30s, 40s, 50s, 60s, >70).53 Thus, it is possible that participants in the present study also 
overestimated their physical activity levels and/or the sample may have been biased by volunteers who 
were more likely to be physically active. On the other hand, it is possible that participants at both ends 




misclassification bias). In addition, it is possible that participants exaggerated their physical activity 
levels to avoid looking inactive to the research assistants, thinking that by reporting their actual levels 
they might be perceived as bearing partial responsibility for their PD. This type of participant bias is 
referred to as social desirability bias and it has been documented in the self-report of physical activity.54 
Lastly, it is important to bear in mind that physical activity also reflects work and it is possible that 
participants may have had occupations that required considerable physical activity.  
 
CONCLUSION 
Our results suggest that people with PD who reported more moderate physical activity from the 3rd 
through 5th decades of life were older at diagnosis when compared to those who reported lower levels 
of physical activity. Our results also indicate that more vigorous physical activity from the 3rd to the 5th 
decades of life was associated with better gait and balance function. As expected, lower MBT scores, 
indicating poor gait and balance performance, were seen in those who had been diagnosed with PD the 
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